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baseline, patients in the EIG reported higher mean scores of physical component
(PCS) (42.7 vs. 35.8) and mental component (MCS) (47.5 vs. 43.0), as well as physical
functioning (48.4 vs. 42.6), role physical (39.0 vs. 30.9), bodily pain (45.2 vs. 38.2),
general health (36.9 vs. 31.4), vitality (52.5 vs. 47.6), social functioning (37.4 vs. 33.0),
role emotional (45.8 vs. 38.7) and mental health (52.8 vs. 46.9). All differences be-
tween the two groups were statistically significant at p 0.05. After 14 weeks of
Infliximab treatment, PCS andMCShad statistically significant improvements (10.7
and 9.8 respectively) from the baseline in the NIG, as well as all sub-domains of
SF-12; in the EIG, there were significant improvements in PCS (8.1), general health
(10.2) and mental health (4.1) from the baseline. CONCLUSIONS: The QOL was
significantly better for patients who received Infliximab therapy than for those not
treated with Infliximab. Infliximab initiating treatment and maintenance therapy
both help improve patients QOL. The results indicate that Infliximab improves the
quality of life of AS patients in China.
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OBJECTIVES: To assess the impact of Rheumatoid Arthritis (RA) and its treatment
on health- related quality of life (HRQOL) of RA patients and identify factors pre-
dicting the risk of disability and their poor Quality of Life (QOL). METHODS: A
observational cross-sectional study was carried out prospectively on 159 RA pa-
tients admitted in a tertiary care hospital. An interview questionnaire was used to
collect data. Patients’ medical records were reviewed. For evaluating the quality of
life and to assess functional disability in RA patients PROMIS-HAQ questionnaires
were used. To measure the disease activity in patients with RA Disease Activity
Score (DAS28) were used. Other outcome measures of disease activity were also
used. RESULTS:Mean age at time of admission was 47.8312.5SD years and 69.5%
of patients were having rheumatoid factor positive. About 82.2% patients had ac-
tive RA. The Mean scores  SDs on composite DAS28-ESR score was 4.9  0.4
reflectingmoderate disease activity andMeanHAQ-DI scorewas 2.30.3 indicating
much functional impairment. The HRQOL of all the patients was significantly
(p0.05) impairedwith a visual analogue scale equal to 56.7. Patientswith active RA
had poorer scores than patients in remission. Patient’s age, age at onset, disease
duration, patient’s assessment of pain were significantly (p0.05) associated with
disease severity and functional impairment. Moreover, disease activity and func-
tional disability measures were strongly associated with HRQOL measures. DAS28
score and family history of RA were the strongest predicators for functional im-
pairment. HAQ-DI score was the only significant predictor for QOL of RA patients.
CONCLUSIONS: HRQOL is an important measure in the regular assessment of the
disease. Present study showed a significant increase in HAQ scores as the physical
disability increased and a highly significant association between the DAS 28, as
well as the HAQ scores of patients with active RA.
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OBJECTIVES: To assess the quality of life (QOL) in rheumatoid arthritis (RA) pa-
tients treated with Infliximab in China.METHODS: A longitudinal survey was con-
ducted between June 10, 2009 and October 20, 2011 in RA patients at 37 urban
hospitals in 21 cities in China. Only respondents who reported with QOL (N363)
were included in this analysis. QOL was measured by Short Form-12 (SF-12) and
each follow-up visit up to 8 visits. RESULTS:Of the survey respondents, 12.7%were
treated with Infliximab (experienced-Infliximab group(EIG)) at baseline and follow
ups, while 87.3% were not treated with Infliximab at baseline but went on Inflix-
imab treatment at the follow ups (new-Infliximab group(NIG)). There were no sig-
nificant differences in age and gender between the two groups. Comparing with
those in the NIG at baseline, patients in the EIG reported higher mean physical
component score (PCS) (38.0 vs. 31.5) and mental component score (MCS) (46.8 vs.
38.3), as well as scores of physical functioning (44.9 vs. 36.6), role physical (34.3 vs.
26.2), bodily pain (41.3 vs. 33.5), general health (34.6 vs. 28.1), vitality (50.0 vs. 43.9),
social functioning (38.6 vs. 25.2), role emotional (40.1 vs. 34.6) and mental health
(50.0 vs. 43.2). All differences between the two groups were statistically significant
(p0.05). After 14 weeks Infliximab treatment, there were significant improve-
ments in PCS (12.2) and MCS (11.1) as well as all sub-domains of SF-12 from the
baseline in the NIG; in the EIG, there were significant improvements in PCS (10.1),
physical functioning (6.14) and general health (7.7) from the baseline.
CONCLUSIONS:RApatients treatedwith Infliximabhave better QOL than those not
treated with Infliximab. Continuing or initiating treatment with Infliximab im-
proves patients QOL. The findings indicate that Infliximab improves the quality of
life of RA patients in China.
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OBJECTIVES: The objective is to investigate changes of QOL, pain, and relevant
factors for Japanese osteoporosis female patients on onceweekly bisphosphonates
(BP) treatment. METHODS: A total of 6003 Japanese female osteoporosis patients
(55 years old and over) on BP treatment were enrolled at 308 study centers between
November 1, 2009 and April 30, 2011 and are being followed for two years. Medical
record review and patient survey are being conducted at the time of enrollment
(M0) as well as 3 (M3), 6 (M6), 12, and 24months after enrollment. We are collecting
information on patient background (e.g., age, concurrent diseases, pharmacother-
apy), QOL scores (Japanese Osteoporosis Quality of Life Questionnaire (JOQOL),
EQ-5D), and pain scores (Visual Analogue Scale (VAS), McGill Pain Questionnaire
(MPQ, Japanese version)). Interim analysis was conducted on data collected from
4,938 patients for M0, 3,375 patients for M3, and 2,465 patients for M6. RESULTS:
The average age was 73.3 (55-100) years old among the 4,938 patients, with 78.6 %
having concurrent diseases (e.g., hypertension, diabetes, osteoarthritis). Regarding
QOL, the total JOQOL scores of M0, M3, and M6 were 65.1, 66.7, and 67.3, respec-
tively, and the M3 and M6 scores were significantly increased in comparison with
M0 (p0.001). EQ-5D utility scores and EQ VAS of M3 andM6were also significantly
higher than M0 (p0.001). With regard to pain, VAS scores at M3 and M6 were
significantly improved from M0 (p0.001) and MPQ scores of M3 and M6 also indi-
cated relief of pain significantly from M0 (p0.01 and p0.001, respectively).
CONCLUSIONS: Improvement in QOL and pain scores of Japanese osteoporosis
patients on BP treatment for 6 months was observed consistently in all indicators
used.
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OBJECTIVES: Perform the measurement of quality of life related to health in pa-
tients with rheumatoid arthritis in Colombia, who are receiving biological therapy.
METHODS: In 252 patients with rheumatoid arthritis receiving biologic therapy, in
December 2010 to May 2011 - established the quality of life reported by the patient
by applying the Health Assessment Questionnaire (HAQ), and its correlation with
the level of disease activity scale as disease Activity Score (DAS28). The analysis
was supplemented by linear regression of HAQ variable depending on other vari-
ables of interest: DAS28, population characteristics, time of use, treatment received
and adverse events (AE). RESULTS: Linear regression showed that three variables
(DAS28 and adverse events) are significant in explaining variations in the quality of
life of patients with RA treated with biological therapy in Colombia. We found that
63,3% of patients with a DAS283.2 have less of one point in the HAQ score, while
in patients with DAS28 3.2, the 71.97% exceeded the HAQ score limit in one point.
The AE is and important variable in determining the quality of life of patients,
although on average only 15.6% of patients with RA showed AE regardless of bio-
logical treatment used. There were no significant differences by treatment type,
age and gender on the population studied. CONCLUSIONS:Quality of life related to
health (HAQ level) varies significantly depending on the state of disease activity
(DAS28) in patients treated with biological therapy.
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OBJECTIVES: To evaluate patient satisfaction with golimumab (GLM) and its auto-
injector in rheumatoid arthritis (RA) patients switched from adalimumab (ADA) or
etanercept (ETA) due to inadequate disease control.METHODS: Data were from an
interim analysis of 200 patients enrolled in GO-SAVE, a GLMmulticenter, assessor-
blinded, switch study of patients with active RA. Patients receiving methotrexate
and having an inadequate response to current treatment with ADA or ETA entered
the screening period at week -6 and continued current treatment. After re-screen-
ing at week 0, all eligible patients were actively switched to open-label GLM 50mg
subcutaneous injections. Satisfaction prior to switching was assessed at week -2
for ADAorweek -1 for ETA. Satisfactionwith and preference for GLMwere assessed
at week 8. RESULTS:Mean (SD) age was 55.9 (11.3) years; 81.5% were female. Mean
(SD) disease duration was 9.8 (9.7) years. Prior to switch, patients were treated with
ADApen (25.5%), ADAprefilled syringe (21.5%), ETA pen (27%), ETA prefilled syringe
(24%), and ETA vial and syringe (2.0%). All 200 patients completed assessment at
week -2 (ADA) or -1 (ETA); 170 completed the assessment at week 8 (GLM). At week
8, 82.9% were satisfied with the overall GLM experience, 80.0% were satisfied with
injection frequency, and 75.3% were satisfied with injection device. Most patients
experienced lower levels of injection related burning (80.0%), stinging (75.3%), dis-
comfort (62.4%), redness (58.8%), and pain (57.6%) with the GLM auto-injector than
with the previous injection device. Patients expressed greater preference for GLM
over their previousmedication (74.0%) and greater preference for the auto-injector
(70.6%) over their previous injection device. CONCLUSIONS: A majority of RA pa-
tients switched to GLM from ADA or ETA were satisfied with their overall GLM
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experience, including preference for GLM and the auto-injector over previousmed-
ication and injection device.
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OBJECTIVES: To examine the association between access restrictions on celecoxib
use and healthcare costs in Medicare patients with arthritis.METHODS: Enrollees
diagnosed with osteoarthritis (OA) or rheumatoid arthritis (RA) between January 1,
2008 and December 31, 2010 (index date) and at least 24 months of continuous
health plan enrollment (I-year pre- and post-index date) were identified from 12
health plans with and without access restrictions to celecoxib in the MarketScan®
Medicare Supplemental and Coordination of Benefits Database. Utilization of celecoxib,
all-cause, gastrointestinal (GI) event-related, and OA/RA-related healthcare utili-
zation and expenditures over a 12-month follow-up period were compared for
enrollees in restricted and unrestricted plans. RESULTS: The restricted group
(N27,595) was similar to the unrestricted group (N57,890) at baseline in terms of
the prevalence of OA/RA, serious GI events, and Charlson Comorbidity Index (CCI)
score; however, celecoxib use was significantly lower in the restricted group (11.8%
vs. 13.5%, p0.001). Total baseline medical costs were significantly higher for the
restricted group as compared to the unrestricted group ($13,641 vs. $10,456,
p0.001), whereas pharmacy costs were lower ($3,873 vs. $4,488, p0.001) for the
restricted group. No differenceswere observed between the two groups inGI event-
related costs ($643 vs. $602, p0.127). Total OA/RA related costs were significantly
higher in the restricted group than the unrestricted group ($9,432 vs. $6,642,
p0.001), which were primarily driven by inpatient costs ($6,215 vs. $3,857,
p0.001). All-cause total costs were also significantly higher in the restricted group
than in the unrestricted group ($25,428 vs. $20,793, p0.001), which were primarily
driven by the costs of inpatient and outpatient services. CONCLUSIONS: Enrollees
in plans with access restrictions to celecoxib had lower utilization of celecoxib. No
differences were observed between the groups in GI event-related costs. All-cause
and OA/RA-related costs, howver, were significantly higher among enrollees in
plans with access restrictions.
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OBJECTIVES: To evaluate the utilization patterns of Medicare Part D beneficiaries
newly started on teriparatide and the association of adherence with fracture out-
comes and health care utilization.METHODS: A retrospective cohort analysis was
performed using medical and pharmacy claims of 761 Humana members aged 18
and older with first prescription fills for teriparatide between January 2008 and
December 2009. Low Income Subsidy enrollees were excluded. Descriptive analy-
ses summarized baseline characteristics, healthcare use, and costs at 12 and 24
months post teriparatide initiation. Adherence was measured by Proportion of
Days Covered (PDC), categorized as high (PDC 80%), intermediate (50% PDC
80%), and low (PDC50%). Multivariate logistic regression was used to evaluate
associations of adherence with fracture rates. RESULTS: Six months before teripa-
ratide initiation, 50.7% of the cohort (386 patients) had at least 1 fracture episode,
although there was low overall comorbidity (Deyo Charlson mean 1.1). At 12
months, 21% of the cohort was highly adherent, whereas at 24 months, only 13%
was highly adherent (272 patients). More low adherent patients visited the ER or
had inpatient visits at 12 months than highly adherent patients (33% vs. 24%;
p0.05; 21% vs. 16%; NS). Total health care costs were greater at 12 months in
highly-adherent patients ($21,033 vs. $15,528; p0.05). Among thehighly adherent,
64%of costswas pharmacy-related. At 12months, only 18%of the 222 patientswith
fractures was highly adherent; this group had the highest overall fracture-related
costs, of which 89% was pharmacy-related. The regression models demonstrated
no significant association between teriparatide adherence and 12-month fracture
outcomes (OR0.81, 95% C.I. 0.53 – 1.24). CONCLUSIONS: Similar to previous stud-
ies of patients with osteoporosis, adherence to prescribed therapywas suboptimal.
Highly-adherent patients appeared to have higher overall costs due to higher phar-
macy costs, whereas patients with low adherence had higher health care utiliza-
tion.
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OBJECTIVES: To estimate national and regional dose escalation patterns over two
years of therapy among biologic naïve RA patients initiating etanercept, adali-
mumab, or infliximab using US managed care data.METHODS: Adult (ages 18-65)
RA patients who did not use RA biologics in the prior six months, initiating etan-
ercept, adalimumab, or infliximab between July 1, 2005 and April 30, 2009 were
identified using the MarketScan® Commercial Database. National and regional
dose escalation rates were evaluated 12 and 24 months after initiation using the
Single Instance Method (one claim with an average weekly dose at least 115%,
130%, or 150% greater than the initial weekly dose) and the Two Instances Method
(two consecutive claims with an average weekly dose 130% greater than the initial
weekly dose). Dose escalation rates were compared using Fisher’s Exact tests.
RESULTS: A total of 2,747 patients met the inclusion criteria (mean age 50 years
(SD10), 74% female). More patients resided in the South (45%) than North Central
(28%), West (17%) or East (10%) US regions. More patients (44%) initiated etanercept
than adalimumab (37%) or infliximab (20%). In the first year of therapy, dose esca-
lation ranged from 0.8%-1.5% for etanercept, 10.8%-12.5% for adalimumab, and
16.4%-42.5% for infliximab using the single instance method; ranges at 24 months
were 0.8%-2.1% for etanercept, 14.3%-17.5% for adalimumab, and 26.4%-57.6% for
infliximab. At 12 and 24 and months respectively, the two instances method
showed lower dose escalation rates for etanercept (0.8%, 0.8%) than adalimumab
(8.7%, 13.3%) or infliximab (22.9%, 37.6%) at the 130% threshold (p0.001). Dose
escalation rates were consistent across US geographic regions, with etanercept
having less dose escalation than adalimumab or infliximab across all regions.
CONCLUSIONS: RA patients initiating etanercept had lower dose escalation rates
than patients initiating adalimumab or infliximab in the first and second year
following therapy initiation and across US geographic regions.
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OBJECTIVES: To estimate dose escalation rates of etanercept, adalimumab, and
infliximab for RA patients initiating and continuing TNF-blockersMETHODS: This
retrospective analysis in the HealthCore Integrated Research Database identified
adult (18-64 years) RA patients with 1 claim for etanercept, adalimumab, or inf-
liximab between July 1, 2007 and January 31, 2010 (first claimindex). Patientswere
continuously enrolled for 6 months prior to index; patients with TNF-blocker
claims within 6 months prior to index were considered continuing therapy. Pa-
tients with other indicated conditions or contraindicated to RA biologic therapy
were excluded. Dose escalation, assessed over a 12-month period of continuous
treatment (60-day gap), was defined as: 1) 2 instances in which subsequent
doses were 130% of index dose or 2) any instances with increased number of
syringe/vial or shortened dosing interval. RESULTS: Overall, 3868 patients were
included (mean age 50.1 years; 74.4% female). Among newpatients (932 etanercept;
267 adalimumab; 292 infliximab), 4.4%, 9.0%, and 42.5% of etanercept, adalimumab,
and infliximab patients, respectively, had 2 instances of dose escalation (p0.001
for all 2-way comparisons). Most new patients (85.3% etanercept; 92.1% adali-
mumab; N/A infliximab) initiated therapy at recommended dose; of these patients,
2.3%, 12.6%, and 59.9% of etanercept, adalimumab, and infliximab patients, respec-
tively, increased by 1 syringe/vial or shortened dosing frequency. Among con-
tinuing patients (1078 etanercept; 480 adalimumab; 819 infliximab), 6.0%, 16.9%,
and 29.1% of etanercept, adalimumab, and infliximab patients, respectively, had
2 instances of dose escalation (p0.0001 for all 2-way comparisons). Most con-
tinuing patients (93.5% etanercept; 95.6% adalimumab; N/A infliximab) received
the index dose at recommended dose; of these, 4.1%, 19.6%, and 79.5% of etaner-
cept, adalimumab, and infliximab patients, respectively, increased by 1 syringe/
vial or shortened dosing frequency. CONCLUSIONS: Etanercept had lower dose
escalation rates for new and continuing patients compared with adalimumab and
infliximab in a large US managed care plan.
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OBJECTIVES: The purpose of this study was to estimate the cost-effectiveness of
alendronate therapy for osteopenic postmenopausal women in Japan.METHODS:
A Markov model with six health states (no fracture, post-vertebral fracture, post-
hip fracture, post-vertebral and hip fracture, bedridden, and death) was developed
to predict lifetime costs and quality-adjusted life years (QALYs) of five years of
alendronate therapy versus no drug treatment in postmenopausal womenwithout
fracture history. Fracture risk associated with age and bone mineral density (BMD)
was derived from epidemiologic studies in Japan. We ran the model with different
combinations of age (65 to 75), BMD (70% - 80% of the young adultmean (YAM)), and
the number of clinical risk factors (CRFs, one to three). Probabilistic sensitivity
analysiswas performed to assess parameter uncertainty.RESULTS:Themodelwas
sensitive to age, BMD, and CRFs. The incremental cost-effectiveness ratio (ICER)
was below $50,000 per QALY in the following scenarios: 1) In 70-year-old women
with BMD 70% of YAM, who had two CRFs, 2) In 75-year-old women with BMD 70%
of YAM, who had two CRFs. In 65-year-old womenwith BMD 70% of YAM, who had
three CRFs, 3) In 70-year-oldwomenwith BMD 70% and 75% of YAM,who had three
CRFs, and 4) In 75-year-old women with BMD 70% and 75% of YAM, who had three
CRFs. Applying a willingness to pay threshold of $50,000 per QALY, the probability
of being cost-effective was estimated to 2.9 %, 36.5%, and 99.2% in 70-year-old
women with BMD 70% of YAM with one CRF, two CRFs, and three CRFs,
respectively. CONCLUSIONS: Whether to treat osteopenic postmenopausal Japa-
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